September 5, 2011
To improve post-marketing safety measures, Korosho will apply new guidelines for “Dear Doctor”letters (emergency safety information or “yellow letters” and safety flash reports (“blue letters” starting October 1. A blue letter for the blood coagulation inhibitor Prazaxa (dabigatran) was issued...read more